產(chǎn)品詳情
簡單介紹：
Anti-Serine carboxypeptidase 1抗體產(chǎn)品質(zhì)量穩(wěn)定，實驗效果明顯，貨期快，價格優(yōu)惠，歡迎垂詢訂購！我公司長期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關(guān)試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-Serine carboxypeptidase 1抗體用于**組化實驗,WB實驗,相應(yīng)的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-Serine carboxypeptidase 1
Cat. Number:
Anti-Serine carboxypeptidase 1抗體KL-7542R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
Vascular smooth muscle activation is a salient feature of several pathological conditions including atherosclerosis, hypertension, Anti-Serine carboxypeptidase 1抗體vein graft failure, restenosis, and transplant arteriopathy. Several new genes whose proteins could lead to such biological effects have been identified. One such protein is RISC. Tissue expression pattern of Retinoid-inducible serine carboxypeptidase (RISC) in human revealed that it was highly expressed in kidney and heart.
Also known as:
HSCP 1; HSCP1; likely homolog of rat and mouse retinoid-inducible serine carboxypeptidase; Retinoid inducible serine Anti-Serine carboxypeptidase 1抗體carboxypeptidase; Retinoid-inducible serine carboxypeptidase precursor; SCP 1; SCP1; SCPEP 1; SCPEP1; Serine carboxypeptidase 1; serine carboxypeptidase 1 precursor protein; RISC_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, .
●
Immunogen: KLH conjugated Anti-Serine carboxypeptidase 1抗體synthetic peptide derived from human RISC/Serine carboxypeptidase 1.
●
Predicted Molecular Weight: 48kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-Serine carboxypeptidase 1抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-Serine carboxypeptidase 1抗體
Optimal working dilutions must be determined by the end user.
